www.innocyto.com.cn

InnoCyto Inc.

15375 Barranca Pkwy, Suite I-103
Irvine, CA 92618
Email: info@innocyto.com
Phone: 1-949-418-7543

# FITC Anti-Human CD279 (PD1) Antibody

| | |
|---|---|
| **Catalog Number:** | 101411, 101412 |
| **Size:** | 25 tests, 100 tests |
| **Target Name:** | CD279, PD1, PD-1 |
| **Regulatory Status:** | RUO |

## PRODUCT DETAILS

| | |
|---|---|
| **Clone:** | 279AM1 |
| **Application:** | Flow Cytometry |
| **Reactivity:** | Human |
| **Format:** | FITC |
| **Isotype:** | Mouse IgG1 |
| **Antibody Type:** | Monoclonal |
| **Formulation:** | Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) BSA |
| **Protein Concentration:** | Supplied at a lot-specific concentration. |
| **Storage&Handling:** | The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze. |
| **Recommended Usage:** | For flow cytometric staining, it is recommended to use 5 uL of this reagent per 0.5-1.0 million cells in a 100 µL volume. Optimal reagent performance should be determined by titration for each specific application. |
| **Excitation Laser:** | Blue Laser (488 nm) |
| **RRID:** | AB_3738614 |

## BACKGROUND INFORMATION

CD279, also known as Programmed cell death 1 (PD-1), cell surface receptor which binds to PD-L1 and PD-L2 ligands; functions as immune checkpoint with important role in down regulating immune system by preventing T-cell activation. Targeted by Nivolumab, Pembrolizumab and other monoclonal antibodies in a new class of cancer drugs. CD279 is expressed predominantly on activated T cells, B cells, and myeloid cells. The interaction with CD279 ligands results in inhibition of T cell proliferation and cytokine secretion.